The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults
The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with either a placebo or risperidone, an atypical antipsychotic that block the subjective effects of psilocybin.
- Status
- recruiting
- Phase
- Phase 2
- Institution
- University of Calgary
- Principal investigator
- Leah Mayo, PhD
- Start date
- 2026-05-15
- End date
- 2028-01-01
- Registry ID
- NCT06768944
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.